Dr. John Cush RheumNow
2 years 11 months ago
Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108).
- 27% flared at 2/3 dose
- 20% at 1/2 dose
- 27% at 1/3 dose
- 25% w/ discontinuation
WHY WOULD YOU DO THIS? I DONT! https://t.co/mIJKaK3LK5 https://t.co/SMGJVfepTl
Dr. John Cush RheumNow
2 years 11 months ago
256 Early RA pt cohort followed 10yrs showed SDAI sustained remission(n 48) had less 10 yr Xray progression (mTSS 4.06), vs sustained LDA (14.6) or MDA/HDA (21.04). Sustained remission pts were younger, lower HAQ & mTSS scores; less need for GC & bDMARDs https://t.co/92L7RTCx82 https://t.co/4uZBydcfRM
Dr. John Cush RheumNow
2 years 11 months ago
Steroid (GC) use is increasing - Claims data from (US, Taiwan, Denmark; n=54,630,437; 2009-2018), GC use increased from 6.4 to 7.7% USA, 16.6 to 18.7% Taiwan, & 1.7 to 2.9% Denmark. Most Rx by PCP to healthy adults; 20-25% Rx for URI. https://t.co/GkQR0hcys1 https://t.co/5fpBv2Kyo8
Dr. John Cush RheumNow
2 years 11 months ago
National Health Information Survey 2022 shows that 41.5% of US adults used the Internet to communicate with a doctor’s office; highest in metropolitan areas and decreasing in urban areas https://t.co/utU2YT7mt5 https://t.co/Y4U8ohy71s
Dr. John Cush RheumNow
2 years 11 months ago
BMJ State of the Art (full read) review of ADVANCES in LUPUS THERAPY (Morand EF, et al).
- Recent SLE RCTs
- Pathogenesis, genetics, epigenetics
- Phenotypes
- Emerging treatments
- Guidelines on Rx
https://t.co/OVJRVA8hoz https://t.co/6Srmo5vNjF
Dr. John Cush RheumNow
2 years 11 months ago
Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/2UZh4zQFEM https://t.co/VRX2Z8YBrC
Dr. John Cush RheumNow
2 years 11 months ago
FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV
A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo or active comparator cohorts).
Dr. John Cush RheumNow
2 years 11 months ago
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/Pi6RbDbroG https://t.co/AWhbVj2QGa
Dr. John Cush RheumNow
2 years 11 months ago
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG
Dr. John Cush RheumNow
2 years 11 months ago
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5
Dr. John Cush RheumNow
2 years 11 months ago
Choosing steroid sparing therapies in #PMR
We have no evidence-based alternative treatment to glucocorticoids in PMR. Few disease-modifying anti-rheumatic drugs, such as methotrexate and leflunomide, are used in daily clinical practice in PMR.
https://t.co/zvfAwc7t1z https://t.co/pAJFHF6hOn
Dr. John Cush RheumNow
2 years 11 months ago
Blinkers and the Unseen Information Gap in #PMR
https://t.co/uZ9qCPmRw9 https://t.co/lrXRdVGNk2
Dr. John Cush RheumNow
2 years 11 months ago
#PMR Mythbusters: PMR Gets 100% Better Within 72 hours
https://t.co/lezwD0J8pL https://t.co/QluGHHnH3X
The treatment of de Quervain tenosynovitis (DQT) was examined by systematic review in JAMA, suggesting that local (US-guided) corticosteroid injection plus a thumb spica immobilization was associated with significant pain-relieving and functional benefits.
